The updated guidance, published March 13 in the Journal of the American College of Cardiology (JACC) and Circulation, replaces the 2018 cholesterol guidelines and reflects a major shift in how doctors ...
The update was jointly published in the journal Circulation and the Journal of the American College of Cardiology. The recent ...
Heart health experts released new guidance to help identify early risk factors for heart disease that go beyond tracking ...
Lipid-lowering therapy can be considered with a 10-year PREVENT-ASCVD risk estimate of 3% to <5% (borderline) and should be considered for those at 5% to <10% (intermediate) 10-year risk. For ...
For primary prevention patients at high risk, such as those with a 10-year risk > 10%, the LDL target is less than 70 mg/dL (class 2a recommendation). For this group, treatment begins with a ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Extent of disease: Patients with 10% or less vitiligo and particularly facial or limited lesions tend to benefit most from ...
An appreciation of the differences in the severity and the symptoms of lichen planopilaris (LPP), an inflammatory scarring alopecia, should be put to use to individualize therapy, according to an ...
- ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule - In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3 ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results